A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors

新型微管抑制剂克服肿瘤多药耐药性

阅读:4
作者:Nannan Ning, Yamei Yu, Min Wu, Ruihong Zhang, Ting Zhang, Changjun Zhu, Lei Huang, Cai-Hong Yun, Cyril H Benes, Jianming Zhang, Xianming Deng, Qiang Chen, Ruibao Ren

Significance

Paclitaxel is a widely used chemotherapeutic drug in patients with multiple types of cancer. However, resistance to paclitaxel is a challenge. This study describes a novel class of microtubule inhibitors with the ability to circumvent multidrug resistance across multiple tumor cell lines. Cancer Res; 78(20); 5949-57. ©2018 AACR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。